FDA has initiated the approval of leucovorin calcium tablets, rushing them to market as part of a push from the Trump administration to identify potential treatments for autism spectrum disorder.
There is a silent crisis in cancer research that underpins nearly all aspects of the work we do to combat this disease.
We are rapidly approaching the Sept. 30 planned expiration of telemedicine coverage under Medicaid. Letting this authorization expire is short-sighted. As an oncologist, I believe there are multiple compelling, non-pandemic reasons for telemedicine to remain a permanent fixture in cancer care.
Working in a comprehensive cancer center requires emotional endurance, strong clinical judgment, and constant interprofessional collaboration, all of which rest on a foundation of personal wellness. For nurses, whose roles are inherently intensive, focusing on wellbeing is integral to their ability to provide safe, compassionate, and effective patient care.
In a press conference on Sept. 22, President Donald Trump, flanked by NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, HHS Secretary Robert Kennedy Jr., and CMS Administrator Mehmet Oz, touted that Tylenol use while pregnant is “probably” the cause of autism.
NIH’s new “unified grant funding policy,” is “not political,” NIH Director Jay Bhattacharya said during his remarks at Research!America’s annual National Health Research Forum Sept. 17.
Monica Bertagnolli, former director of NIH and NCI, is on the path to becoming the next president of the National Academy of Medicine.
Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care.
Twelve leading research teams from around the world have been shortlisted for Cancer Grand Challenges’ fifth funding round. The teams will present final proposals to a panel of leading international scientists in December, with winners receiving up to £20 million each.
Nicholas Richardson was named vice president of clinical development at Precision for Medicine, a company focused on biomarker-driven clinical research and development.
